Merck & Co is a global healthcare company that specializes in the development, manufacturing, and marketing of pharmaceutical products and vaccines. The company is dedicated to improving health outcomes through innovative research and is known for its focus on areas such as oncology, infectious diseases, and immunology. In addition to its pharmaceutical offerings, Merck actively engages in the discovery of new biologics and therapies, working to address some of the most pressing health challenges worldwide. Through its commitment to scientific excellence and patient care, Merck plays a critical role in advancing public health and enhancing quality of life globally. Read More
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for ENFLONSIA™ (clesrovimab-cfor) to expand its indication to include prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in children under two years of age at increased risk for severe RSV disease through their second RSV season. The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of March 22, 2027.
Merck & Co., Inc. (NYSE:MRK) reported second-quarter revenue of $16.6 billion, up 5% from a year earlier, driven by oncology, animal health and contributions from newer product launches. Revenue increased 4% excluding foreign exchange, according to Chief Financial Officer Caroline Litchfield.
T
Global pharmaceutical company Merck (NYSE:MRK) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.1% year on year to $16.61 billion. The c...
Global pharmaceutical company Merck (NYSE:MRK) announced better-than-expected revenue in Q2 CY2026, with sales up 5.1% year on year to $16.61 billion. The co...
Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2026.
Merck & Co., Inc. (NYSE:MRK) outlined its HIV treatment and prevention strategy at an investor event following the International AIDS Conference, highlighting Phase III results for a once-weekly oral HIV regimen and its plans for a monthly oral pre-exposure prophylaxis, or PrEP, candidate.
Comp
Global pharmaceutical company Merck (NYSE:MRK) will be announcing earnings results this Tuesday before market hours. Here’s what investors should know. Merck...
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company’s common stock for the fourth quarter of 2026. Payment will be made on October 7, 2026, to shareholders of record at the close of business on September 15, 2026.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced early components of a multi-faceted strategy to provide rapid, broad and sustainable access in low- and middle-income countries (LMICs) to alimatravir (MK-8527), an investigational, novel, once-monthly oral pill as pre-exposure prophylaxis (PrEP) for the prevention of HIV-1, following regulatory approval. Initial access plans as part of Merck’s broader strategy include establishing early generic licensing covering 129 LMICs; supporting targeted, regional manufacturing capabilities in Africa and Latin America; and investing early in product manufacturing to enable timely access and availability in regions of high unmet need. The first steps of this strategy are being announced in the lead up to the 26th International AIDS Conference in Rio de Janeiro, Brazil.
